Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 08, 2024

BUY
$1.11 - $2.34 $11,555 - $24,359
10,410 Added 28.09%
47,472 $110,000
Q3 2023

Oct 20, 2023

BUY
$1.06 - $3.91 $16,666 - $61,476
15,723 Added 73.68%
37,062 $47,000
Q2 2023

Jul 11, 2023

BUY
$3.08 - $9.55 $65,724 - $203,787
21,339 New
21,339 $70,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $198M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.